| This week's sponsor is Patheon, part of Thermo Fisher Scientific. | | | Quickly proving efficacy in First-in-Human clinical trials is a make-or-break milestone for small biopharms whose hopes hinge upon one or two molecules. Read how CDMOs are helping these cash-strapped companies get to clinic faster. |
Today's Rundown FierceBiotech BIO breakfast—CAR-T 2.0: Biomedical science at the cutting edge BIO: Lightning round with John Maraganore Biogen inks $357M option deal for TMS’ stroke drug [Sponsored] It Might Be a Bumpy Ride: Why Life Sciences Companies Should Consider Embracing the New Wave of Change Ex-Takeda executive takes up CMO post at CD47 biotech Trillium Trial suggests KaNDy’s menopause drug could be better than HRT Oncologie kicks off trans-Pacific operations with $16.5M in seed funding Servier opens Kendall Square site, plans Chinese office to access external innovation Eyeing the most lucrative vaccine market, SutroVax nabs $85M and Moncef Slaoui as chairman Featured Story | | | Thursday, June 7, 2018 BOSTON—Every year at the BIO International Convention, FierceBiotech hosts a panel discussion about what we see as the biggest R&D talking point of the year. We also look further at what’s on the horizon. This year, that is CAR-T 2.0. |
|
|
| This week's sponsor is SNBL. | | | Does Your CNS Program Need a Boost? The Shortest Distance is a Straight Line. Nose-to-Brain
Brain delivery can be a hurdle for CNS drugs targeting unmet medical needs. Our technology can deliver your drug directly to the brain. Find out how! |
Top Stories Thursday, June 7, 2018 BOSTON—We caught up with BIO Board Chair and Alnylam CEO John Maraganore at this year's meeting and asked him about a range of topics, including drug pricing, immigration and the culture at biotech versus pharma companies. Thursday, June 7, 2018 Biogen signed a deal for an exclusive chance to acquire TMS’ treatment for restoring blood flow after acute ischemic stroke, which is currently being evaluated in a placebo-controlled phase 2 study in Japan. Monday, June 4, 2018 Changes in technology and geopolitics, coupled with U.S. tax reform and new financial accounting standards, are creating disruption in accounting and financial reporting for life sciences companies. Thursday, June 7, 2018 Trillium Therapeutics has named Yaping Shou, M.D., Ph.D., as its CMO. Shou joins the anti-CD7 cancer biotech from Takeda’s oncology department, where she worked as executive medical director. Thursday, June 7, 2018 New women’s health biotech KaNDy Therapeutics—rumored to have attracted buyout interest from Allergan—has just reported data on its lead product that could enhance its allure. Thursday, June 7, 2018 Immuno-oncology startup Oncologie has formally launched its operations in Boston and Shanghai following $16.5 million in seed funding, with the goal of delivering new cancer therapies in the U.S. and Chinese markets simultaneously. Thursday, June 7, 2018 Servier has opened a site in Kendall Square and staffed it with people from Biogen and the University of Massachusetts to find R&D and licensing opportunities. News of the office opening comes shortly after the French company stepped up its U.S. strategy with a $2.4 billion deal for Shire’s oncology unit. Thursday, June 7, 2018 With ambitions to take on global vaccine leaders in the industry's top field, SutroVax is revving up operations with series C funding and a prominent Big Pharma executive as chair. The target? Pneumococcal vaccines such as Pfizer’s Prevnar. | This week's sponsor is LabConnect. | | | SciOps Provides Solutions for Lost Samples, Missed Timelines and Scientific Personnel Needs
Managing outsourced studies can be challenging. Read how our team’s functional and strategic resourcing services allow you to focus on other core competencies. |
Enrollment Showcase | | | Sponsored by: Bioinformatics at UTHealth SBMI UTHealth SBMI now offers a M.S. track in clinical and translational bioinformatics. |
|
|
Resources Sponsored by: Blue Latitude Health Blue Latitude Health explores the commercial barriers and new stakeholder connections for pharma companies developing precision medicines, and reveals how to grasp novel opportunities in the new era of healthcare. Presented By: Covance A solid RBM plan will not only help you comply with the ICH guidelines, but will help you mitigate risks which could ultimately delay your trials and increase costs. Download today! Presented by: Patheon, part of Thermo Fisher Scientific “Faster and better” has become the mantra for biopharmaceutical companies as they face intense pressure to get therapies to market faster. Quickly proving efficacy in first-in-human (FIH) trials is a make-or-break milestone for these cash-strapped companies whose hopes hinge upon one or two molecules. Read how CDMOs are responding to this pressure. Sponsored by: Seton Hall Law 4-day interactive educational program trusted by multi-national companies as part of their compliance training for employees. Explore legal, regulatory and ethical issues faced by pharmaceutical, biotech and medical device manufacturers operating globally. Visit event homepage for session topics. Sponsored by: Docusign Life science companies are experiencing a significant transformation in how they bring new products to market. Drug Approval, Manufacturing Quality & Regulation 2018 | Online Innovation, Collaboration and Entrepreneurship in Drug Discovery June 28, 2018 | Cambridge, UK CBI’s 14th Annual Medical Device Compliance Congress (MDCC) June 14-15, 2018 | Chicago, IL Sensors Expo & Conference Conference & Expo: June 26-28, 2018 | Pre-Conference Symposia: June 25, 2018 | San Jose, CA Drug Development Boot Camp® 2018 November 14-15, 2018 | Boston, MA | Register and start preparing Today! | 